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Abstract
Background: The PACE trial compared the effectiveness of adding adaptive pacing therapy (APT), cognitive behaviour
therapy (CBT), or graded exercise therapy (GET), to specialist medical care (SMC) for patients with chronic fatigue syndrome.
This paper reports the relative cost-effectiveness of these treatments in terms of quality adjusted life years (QALYs) and
improvements in fatigue and physical function.
Methods: Resource use was measured and costs calculated. Healthcare and societal costs (healthcare plus lost production
and unpaid informal care) were combined with QALYs gained, and changes in fatigue and disability; incremental cost-
effectiveness ratios (ICERs) were computed.
Results: SMC patients had significantly lower healthcare costs than those receiving APT, CBT and GET. If society is willing to
value a QALY at £30,000 there is a 62.7% likelihood that CBT is the most cost-effective therapy, a 26.8% likelihood that GET is
most cost effective, 2.6% that APT is most cost-effective and 7.9% that SMC alone is most cost-effective. Compared to SMC
alone, the incremental healthcare cost per QALY was £18,374 for CBT, £23,615 for GET and £55,235 for APT. From a societal
perspective CBT has a 59.5% likelihood of being the most cost-effective, GET 34.8%, APT 0.2% and SMC alone 5.5%. CBT and
GET dominated SMC, while APT had a cost per QALY of £127,047. ICERs using reductions in fatigue and disability as
outcomes largely mirrored these findings.
Conclusions: Comparing the four treatments using a health care perspective, CBT had the greatest probability of being the
most cost-effective followed by GET. APT had a lower probability of being the most cost-effective option than SMC alone.
The relative cost-effectiveness was even greater from a societal perspective as additional cost savings due to reduced need
for informal care were likely.
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Introduction
Chronic fatigue syndrome (CFS) describes a condition of
chronic disabling fatigue for which there is no other explanatory
condition. It has a prevalence of 0.2–2.6% of people worldwide
[1]. CFS can disrupt employment and necessitates support from
families in addition to formal healthcare [2,3]. Therapies have
been developed for CFS, particularly cognitive behaviour therapy
and graded exercise therapy [4]. In the PACE trial we compared
the clinical effectiveness of these two therapies with adaptive
pacing therapy, when added to specialist medical care, and with
specialist medical care alone [5]. Adding cognitive behaviour
therapy or graded exercise therapy to specialist medical care was
found to be more effective in reducing both fatigue and disability
than adding adaptive pacing therapy or specialist care alone.
The aims of this paper are to compare (i) the one-year service
and societal costs associated with specialist medical care (SMC)
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plus cognitive behaviour therapy (CBT), SMC plus graded
exercise therapy (GET), SMC plus adaptive pacing therapy
(APT) and SMC alone, and (ii) the one-year cost-effectiveness of
CBT, GET, APT and SMC in terms of gains in quality-adjusted
life years (QALYs) and reductions in fatigue and disability.
Methods
Study Design and Participants
PACE was a parallel four-arm, multi-centre, randomised
controlled trial with participants recruited from consecutive new
outpatients attending six secondary care specialist CFS clinics in
the UK. Participants were selected using the Oxford diagnostic
criteria for CFS which required disabling fatigue to be the primary
problem, in the absence of an exclusionary medical or psychiatric
diagnosis [6]. Other inclusion criteria were: aged 18 years or more,
a binary score of 6 or more out of 11 on the Chalder fatigue
questionnaire [7], and a score of 65 or less out of 100 on the Short
Form-36 physical function sub-scale [8]. Exclusionary criteria and
allocation procedures have previously been described [5]. Written
consent was obtained from all participants. Ethical approval was
given by the West Midlands Multi-centre Research Ethics
Committee (MREC 02/7/89).
Interventions
Treatment manuals are available at www.pacetrial.org. These
specified at least three sessions of SMC for all participants and up
to 15 individual therapy sessions for those allocated to APT, CBT
and GET. SMC was provided by CFS doctors and consisted of
provision of information about CFS, advice for coping, and
symptomatic pharmacotherapy. APT involved management of
energy expenditure and activity, under occupational therapist
supervision, and aimed at helping the patients to adapt by ‘pacing’
their activity. CBT, delivered by clinical psychologists or nurse
therapists, aimed to change behavioural and cognitive factors
assumed to be responsible for perpetuating symptoms and
disability. GET, delivered by physiotherapists, aimed to return
the participant to an appropriate level of physical activity by
increasing exercise in a gradual and personalised manner.
Outcomes
Quality-adjusted life years (QALYs) were generated from the
EQ-5D health-related quality of life questionnaire at baseline, and
at 12, 24 and 52 weeks after randomisation [9]. The EQ-5D
measures the following domains: mobility, self-care, usual activ-
ities, pain/discomfort, anxiety/depression. Each was coded as 1
(no problem), 2 (moderate problems) or 3 (severe problems) and
UK-specific utility weights attached [10]. The accrual of QALYs
was calculated using area under the curve, assuming a linear
change between each available time point. Differences in baseline
utility scores were controlled for when making comparisons
between treatment groups [11].
Interpretation of condition specific outcome measures in
economic evaluations is difficult and to aid interpretability we
assessed the cost per person achieving a clinically important
change. Two variables were created to indicate whether patients
achieved a two-point improvement on the Chalder fatigue
questionnaire (CFQ) and an eight-point change on the Short
Form-36 physical function sub-scale (SF36 PF) [7,8]. These
changes were assumed to be clinically significant by White et al
[5].
Service Use and Costs
In our analysis we adopted both a healthcare and a societal
perspective. (The latter includes lost employment and unpaid
informal care as well as health costs.) The number and duration of
APT, CBT, GET and SMC treatment sessions actually delivered
were recorded and time added for preparation, related corre-
spondence, and supervision. It was assumed that the ratio of time
spent on patient-related versus support activities was 1:0.3 and that
capital and administrative overheads were 46% [12]. The cost per
hour of therapy was £110 for CBT and £100 for APT and GET.
The cost of SMC was based on the cost per hour of consultant
physician time in face-to-face contact with patients, which was
£169 [12].
Services used during the six months before randomisation and
during the 12 months after randomisation were measured with the
Client Service Receipt Inventory (CSRI) [13]. (The CSRI was
used at 6 and 12 months after randomisation and the data were
combined.) Services are listed in Appendix S1. Where available,
unit costs were obtained from nationally recognised sources
[12,14]. Specific types of medication (analgesics, antidepressants,
anxiolytics, and hypnotics) were recorded and average costs
assumed for each type [15].
Unpaid informal care from family/friends was measured by
asking patients how many hours of care were provided because of
fatigue. Alternative methods exist for valuing informal care, with
the opportunity cost and replacement cost approaches being the
most recognised. We adopted the former and valued informal care
at £14.60 per hour based on national mean earnings [16]. Days
lost by patients from work, and reduced hours while at work, due
to fatigue were also recorded. The human capital approach was
used with the value of lost work-time to society assumed to be
reflected by national mean age and gender-specific wage rates and
combined with the lost employment data to generate lost
production costs [16].
We excluded welfare benefits or payments from other sources
such as private pensions and income protection schemes from the
economic costs. However, we do report the receipt of these given
that they are important financial outlays.
Analysis
Comparisons were made between SMC alone and each of APT,
CBT and GET. Healthcare, informal care and societal costs
(including lost production and informal care) during the 12 months
after randomisation in each treatment group were compared using
regression models controlling for baseline costs and clustering for
centre. Confidence intervals were generated around the cost
differences using non-parametric bootstrapping [17].
Cost-effectiveness analyses combining data on incremental costs
and outcomes can be compared for each treatment group in turn
against each of the others. If costs for one treatment were lower
and outcomes better than another treatment, that treatment was
defined as ‘dominant’. If costs were higher (lower) and outcomes
better (worse) then an incremental cost-effectiveness ratio (ICER)
was calculated (i.e. extra cost divided by extra outcome). The
ICER indicates the cost per QALY gained or cost per unit
reduction in fatigue or disability for one treatment against another.
The threshold used to assess the QALY ICERs was £30,000.
ICERs constructed with the CFQ and SF-36 PF data used the
differences in proportions achieving clinically important changes.
The resultant ICER indicates the cost of one extra person
achieving such a change as a result of using APT, CBT or GET in
addition to SMC compared to SMC alone.
Interpretation of the cost-effectiveness results was made using
cost-effectiveness acceptability curves [18]. Net benefit values were
Cost-Effectiveness of Therapies for CFS
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computed for each study participant, defined as the value of a
QALY multiplied by the number of QALYs gained minus the cost
(from both healthcare and societal perspectives). We used QALY
values ranging from £0 to £60,000 in increments of £5000. For
each QALY value, regression models were used to determine the
difference in net benefit between the four treatment arms,
controlling for baseline utility and costs. Bootstrapping with
1000 resamples allowed the proportion of resamples showing
APT, CBT, GET and SMC as having the highest net benefit (and
to be most cost-effective) to be computed and plotted.
Sensitivity analyses were conducted around key parameters in
the analyses about which assumptions had been made. Specifically
we (i) estimated the cost of therapy required to reverse the findings
from the initial analysis, (ii) used the minimum wage rate
(£5.93 per hour) and the unit cost of a homecare worker to value
informal care, (iii) used the minimum wage rate to value lost
production, (iv) reduced the cost of standardised medical care by
50% to reflect the possibility of it being provided by a less senior
doctor.
Role of the Funding Source
The sponsors of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of the
report. All named authors had access to the data, commented
drafts, and approved the final report. Members of the writing
group had responsibility for submitting the report, and PM had
final responsibility for the decision to submit for publication.
Results
Sample Characteristics
641 patients were recruited, one of whom withdrew consent.
Demographic and clinical characteristics of participants were
similar across treatments, apart from a shorter duration of
illness in SMC (Table 1). Costs and QALYs were available for
570 (89%) participants (ranging from 85% GET to 93% SMC).
Those for whom both cost and QALY data were available were
significantly more likely to be of Caucasian ethnicity (94.6% v
86.4%, fishers exact test p = 0.027). There were no other
statistically significant differences in the background character-
istics shown in Table 1. Further details of the sample have been
reported previously [5].
Service Use and Lost Employment before Randomisation
During the 6 months before randomisation, most participants
had used primary care services and over 40% other (secondary
care) doctors (Table 2). Around two-thirds had used other health
service professionals, between one-quarter and one-third had used
complementary healthcare practitioners; most used medication.
The intensity of service use (mean contacts for those using them)
revealed no substantial differences between treatment groups. Lost
employment was common in all treatment groups.
Service Use and Lost Employment after Randomisation
During the 12 months after randomisation, SMC participants
had a higher mean number of specialist medical care contacts than
those allocated to additional therapy. The number of therapy
contacts did not differ between APT, CBT and GET groups.
Other service use did not greatly differ between treatments during
this period, although informal care hours for APT and SMC were
higher than for CBT and GET. There was no clear difference
between treatments in terms of lost employment.
Costs
Costs are shown in Table 3. Controlling for baseline, healthcare
costs after randomisation were significantly lower for SMC than
for APT (difference £840, 95% CI £637 to £1117), CBT
(difference £904, 95% CI £613 to £1205) and GET (difference
£829, 95% CI £534 to £1165). The differences between the APT,
CBT and GET groups were small and non-significant.
Informal care costs of patients allocated to APT were
significantly higher than for CBT (difference £1580, 95% CI
£139 to £3132) and GET (difference £1588, 95% CI £442 to
£2694). Patients allocated to SMC also had higher informal care
costs than CBT (difference £1165, 95% CI £289 to £2194) and
GET (difference £1173, 95% CI £740 to £1569). Lost production
costs were significantly higher for APT compared to CBT
(difference £1279, 95% CI £141 to £2772). Societal costs (i.e.
healthcare, informal care and lost production costs) were
Table 1. Baseline demographic and clinical data.
Treatment (n) APT (159) CBT (161) GET (160) SMC (160)
Demographic data
Age (years): Mean (SD) 39 (11) 39 (12) 39 (12) 37 (11)
Female 121 (76) 129 (80) 123 (77) 122 (76)
Caucasian 146 (92) 151 (94) 148 (93) 150 (94)
Any ME group membership 31 (19) 26 (16) 25 (16) 23 (14)
Clinical data
International CFS criteria 107 (67) 106 (66) 106 (66) 108 (68)
London ME criteria 81 (51) 84 (52) 84 (53) 80 (50)
Any depressive disorder 54 (34) 52 (32) 54 (34) 53 (33)
Any psychiatric disorder 75 (47) 75 (47) 73 (46) 77 (48)
Duration of illness (months) Median (25th, 75th quartiles) 33 (16, 69) 36 (16, 104) 35 (18, 67) 25 (15, 57)
BMI (m2/Kg) Mean (SD) 25.9 (5.5) 25.4 (5.2) 25.5 (4.6) 25.1 (4.5)
Data are N (%) unless otherwise stated.
APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care alone, ME = myalgic
encephalomyelitis, BMI = body mass index.
doi:10.1371/journal.pone.0040808.t001
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significantly lower for patients allocated to CBT compared to APT
(difference £2607, 95% CI £432 to £5585). Other differences
were not statistically significant.
Welfare Benefits and Other Financial Payments
Receipt of benefits due to illness or disability increased slightly
from baseline to follow-up (Table 4). Patients in the SMC group
had the lowest level of receipt at baseline but the figures at follow-
up were similar between groups. Relatively few patients were in
receipt of income-related benefits or payments from income
protection schemes and differences between groups were not
substantial.
Outcomes
APT, CBT and GET each resulted in improvements in health-
related quality of life (measured with the EQ-5D) while SMC
produced little change (Table 5). CBT produced the largest QALY
gain, significantly more than SMC. After controlling for baseline
utility, the difference between CBT and SMC was 0.05 (95% CI
0.01 to 0.09). No other differences between treatment groups were
statistically significant. The number (%) of patients achieving a
clinically significant reduction in fatigue in each group was: APT
96 (64.0), CBT 113 (76.4), GET 123 (79.9), and SMC 98 (64.9).
This difference was statistically significant (Fisher’s Exact test,
p = 0.002). The number (%) of patients achieving a clinically
significant reduction in disability in each group was: APT 75
(49.0), CBT 105 (71.0), GET 108 (70.1), and SMC 88 (57.9). This
Table 2. Service use and lost employment at baseline and follow-up.
6-month pre-randomisation period
N (%) using services Mean (sd) contacts per user
Service APT (n =159) CBT (n =161) GET (n =160) SMC (n=160) APT (n=159) CBT (n=161) GET (n=160) SMC (n=160)
Primary care 154 (97) 154 (96) 157 (98) 156 (98) 5.3 (3.9) 5.6 (4.6) 5.4 (3.3) 5.9 (4.5)
Other doctor 66 (42) 68 (42) 71 (44) 71 (44) 2.3 (2.0) 2.5 (2.0) 2.0 (1.4) 2.3 (2.5)
Health professional 95 (60) 105 (65) 109 (68) 109 (68) 3.7 (5.1) 3.8 (5.5) 3.2 (3.8) 3.6 (5.6)
Inpatientb 6 (4) 7 (4) 10 (6) 15 (9) 1.3 (0.5) 1.7 (1.1) 1.0 (0.0) 2.0 (2.3)
Accident and emergency 13 (8) 16 (10) 20 (13) 19 (12) 1.3 (0.9) 1.1 (0.3) 1.3 (0.9) 1.4 (0.6)
Medicationb 118 (74) 130 (81) 121 (76) 122 (76) – – – –
Complementary healthcare 50 (31) 41 (25) 55 (34) 52 (33) 7.1 (6.8) 6.5 (6.3) 8.2 (9.3) 7.5 (8.7)
Other health/social services 157 (99) 159 (99) 160 (100) 160 (100) 16.0 (9.7) 16.8 (9.6) 16.2 (8.0) 16.0 (8.9)
Informal cared 118 (74) 106 (66) 120 (75) 128 (80) 11.5 (11.1) 10.4 (8.3) 9.6 (9.3) 12.3 (13.7)
Lost employmente 127 (80) 135 (84) 132 (83) 137 (86) 81.0 (53.3) 85.3 (52.7) 83.0 (53.7) 75.5 (50.6)
12-month post-randomisation period
N (%) using services Mean (sd) contacts per user
Servicea APT (n =146) CBT (n =145) GET (n =140) SMC (n=148) APT (n=159) CBT (n=161) GET (n=160) SMC (n=160)
Primary care 134 (92) 134 (92) 134 (96) 139 (94) 7.1 (5.7) 6.6 (5.6) 6.3 (3.9) 7.0 (4.5)
Other doctor 60 (41) 71 (49) 65 (46) 67 (45) 2.4 (2.2) 2.5 (2.0) 3.1 (2.9) 3.2 (5.6)
Health professional 109 (75) 110 (76) 115 (82) 118 (80) 5.3 (7.9) 4.4 (5.9) 5.6 (8.3) 4.7 (4.7)
Inpatientb 17 (12) 16 (11) 21 (15) 18 (12) 3.2 (3.5) 1.4 (0.7) 2.2 (2.4) 2.2 (2.3)
Accident and emergency 26 (18) 22 (15) 14 (10) 19 (13) 1.1 (0.3) 1.4 (0.7) 1.6 (1.2) 1.8 (1.2)
Medicationc 112 (77) 117 (81) 108 (77) 124 (84) – – – –
Complementary healthcare 42 (29) 32 (22) 39 (28) 47 (32) 8.5 (9.6) 10.0 (14.4) 12.3 (12.0) 10.2 (11.1)
Informal cared 108 (74) 96 (66) 98 (70) 111 (75) 11.0 (10.7) 8.0 (8.6) 7.7 (8.7) 11.4 (11.6)
Other health/social services 108 (74) 110 (76) 106 (76) 105 (71) 6.3 (6.7) 6.3 (9.2) 7.3 (8.1) 7.6 (10.2)
Therapy 146 (100) 145 (100) 140 (100) – 13.0 (2.4) 13.3 (2.4) 12.9 (2.5) –
Standardised medical care 146 (100) 145 (100) 138 (99) 148 (100) 3.6 (1.7) 3.7 (2.2) 3.6 (1.4) 5.0 (2.7)
Informal cared 108 (74) 96 (66) 98 (70) 111 (75) 11.0 (10.7) 8.0 (8.6) 7.7 (8.7) 11.4 (11.6)
Lost employmente 124 (86) 122 (84) 118 (86) 130 (89) 148.6 (109.2) 151.0 (108.2) 144.5 (109.4) 141.7 (107.5)
asee Appendix S1 for services included in these categories,
bcontacts measured in bed days,
cquantity unreported as average cost assumed for each patient using medication,
dcontacts measured in weekly hours,
edays lost from work.
APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care alone.
doi:10.1371/journal.pone.0040808.t002
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difference was also statistically significant (Fisher’s Exact test,
p,0.001).
Cost-effectiveness from a Healthcare Perspective
At a threshold of £30,000 per QALY, CBT had a 62.7%
likelihood of being the most cost-effective option from a healthcare
perspective followed by GET at 26.8% (Figure 1). APT had a
2.6% likelihood of being most cost-effective, which was less than
the figure for SMC (7.9%).
The ICERs showing the healthcare cost per QALY for CBT
and GET compared to SMC were both below the threshold of
£30,000 while the ICER for APT compared to SMC was
substantially higher (Table 6). The healthcare costs per extra
person with a clinically significant reduction in fatigue and
disability are also shown. It is clear that achieving such a reduction
for one person is associated with a much lower cost, compared to
SMC, for CBT or GET than it is for APT. In fact, SMC dominates
(i.e. has better outcomes and lower costs) APT with regard to
disability.
Cost-effectiveness from a Societal Perspective
Again at a threshold of £30,000 per QALY, CBT had a 59.5%
likelihood of being the most cost-effective option from a societal
perspective (Figure 2). GET had a likelihood of 34.8% while APT
and SMC had likelihoods of 0.2% and 5.5% respectively.
CBT and GET both dominated SMC from a societal
perspective with regard to QALYs gained and reductions in
fatigue and disability. Compared to SMC, APT had an
Table 3. Service costs at baseline and follow-up.
6-month pre-randomisation period
Mean (SD) cost (2009/10 UK pounds)
Servicea APT (n =159) CBT (n =161) GET (n=160) SMC (n=160)
Primary care 163 (177) 150 (166) 148 (146) 171 (160)
Other doctor 159 (339) 200 (551) 137 (232) 145 (338)
Health professional 85 (193) 121 (297) 98 (213) 86 (163)
Inpatient 13 (72) 23 (129) 22 (90) 69 (352)
Accident and emergency 10 (42) 10 (32) 16 (52) 16 (47)
Medication 46 (38) 48 (37) 45 (36) 41 (33)
Complementary healthcare 89 (201) 67 (169) 112 (266) 98 (242)
Other health/social services 187 (649) 136 (185) 131 (137) 145 (201)
Informal care 3233 (4097) 2601 (3181) 2719 (3441) 3732 (5018)
Lost employment 7822 (6770) 7978 (6282) 8095 (6745) 7499 (6094)
Total health costs 752 (901) 755 (857) 709 (485) 770 (736)
Total societal costs 11,807 (8223) 11,333 (7452) 11,523 (7705) 12,001 (8510)
12-month post-randomisation period
Mean (SD) cost (2009/10 UK pounds)
Servicea APT (n =146) CBT (n =145) GET (n=140) SMC (n=148)
Primary care 178 (217) 165 (161) 170 (165) 198 (186)
Other doctor 177 (416) 169 (332) 188 (319) 238 (877)
Health professional 120 (164) 123 (178) 152 (230) 168 (345)
Inpatient 142 (619) 54 (180) 132 (500) 99 (414)
Accident and emergency 19 (44) 20 (53) 15 (57) 22 (71)
Medication 70 (68) 78 (68) 70 (54) 77 (65)
Complementary healthcare 98 (256) 89 (315) 137 (335) 129 (313)
Other health/social services 141 (281) 111 (299) 146 (242) 118 (251)
Therapyb 1040 (275) 1198 (366) 935 (300) –
Standardised medical careb 227 (191) 230 (248) 213 (155) 358 (224)
Informal care 6196 (7875) 4008 (6046) 4073 (6107) 6507 (8521)
Lost employment 14,865 (13,115) 13,958 (12,044) 14,638 (13,406) 14,157 (12,568)
Total health costs 2256 (1220) 2322 (870) 2224 (1073) 1424 (1276)
Total societal costs 23,317 (17,284) 20,288 (14,363) 20,935 (15,531) 22,088 (17,438)
asee Appendix S1 for servpone.0040808.g003.tifices included in these categories;
btherapy and SMC costs are for 640 participants.
APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care alone.
doi:10.1371/journal.pone.0040808.t003
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incremental cost per QALY substantially higher than the £30,000
threshold while the cost per person with a clinically significant
reduction in fatigue was high. SMC dominated APT with regard
to disability.
Sensitivity Analyses
The healthcare costs per QALY gained for CBT and GET
compared to SMC were below the cost-effectiveness threshold of
£30,000. The cost of CBT would need to increase by 45% and
GET by 22% for the cost per QALY to reach £30,000. Therapy
costs for APT would need to fall 35% for APT to have a cost per
QALY compared to SMC of £30,000. No other sensitivity
analyses (i.e. changing the value of informal care, lost employment
and standardised medical care) had a large impact on cost-
effectiveness.
Discussion
Main Findings
We found that adding APT, CBT or GET to SMC resulted in
significantly increased healthcare costs. For CBT and GET the
healthcare costs per QALY gained were lower than the
conventional £30,000 threshold used in England, indicating
cost-effectiveness; for APT the cost per QALY was in excess of
this threshold.
The major contributors to societal costs were lost employment
and informal care costs. The cost-effectiveness of CBT was more
apparent from this perspective than from the narrower healthcare
perspective; CBT dominated APT, GET and SMC, while GET
dominated APT and SMC. Informal care costs were substantial
for each group and significantly lower after receiving CBT and
GET when compared to APT and SMC. CFS affects patients in
many ways and can have a major effect on family members. This
study suggests that CBT and GET could ameliorate this effect.
However, with the exception of a difference between CBT and
APT, there were no significant differences in either lost work time
or benefits between the treatments during follow up. In fact,
benefits increased across all four treatments.
There are few previous studies with which to compare our
results. The additional healthcare costs per QALY gained with
CBT and GET compared to SMC alone in this study were
£18,374 and £23,615 respectively. These costs are substantially
lower than the figure of an additional J51,642 per QALY
reported for CBT compared to usual care in a Dutch study [19].
The QALY gain for CBT over usual care in that study was slightly
less than we found which may account for some of this difference,
given that average costs were similar. Two other studies have
assessed cost-effectiveness of treatments for CFS [20,21]. Howev-
er, only a minority of patients in both of these studies had CFS and
neither used QALYs as an outcome measure.
This study has found that CBT and GET are cost-effective
options for treating patients with CFS. However, for patients to
benefit from these therapies there needs to be investment to
provide the staff trained to deliver them. The findings we report
suggest that such investment would be justified in terms of
improved quality of life of patients and would actually be cost
saving if all costs including societal costs are considered.
Limitations
The study has limitations. First, we relied on self-reported
information on service use and lost employment. There may be
issues of accuracy with this approach but it was largely
unavoidable given the need for a comprehensive perspective.
Other studies have shown this to be an acceptable method [22–
24]. The accuracy of our cost estimates was enhanced by the direct
recording of the number and duration of therapy sessions which
formed around half of the costs. Second, average medication costs
were assumed for the cost periods. While greater variation would
be expected, medication costs are small compared to other service
costs. Third, we used the EQ-5D to generate QALY values. This is
a recommended method in England, but the sensitivity of the
measure in relation to changes in clinical measures in the CFS
area has not yet been established. Fourth, we made assumptions
Table 4. N (%) receiving welfare benefits or other financial payments.
Time point APT(n=141) CBT(n =138) GET(n=134) SMC(n =143)
Income benefits
6-month pre-randomisation period 28 (18) 16 (10) 22 (14) 17 (11)
12-month post-randomisation period 33 (22) 19 (13) 29 (20) 20 (14)
Illness/disability benefits
6-month pre-randomisation period 42 (26) 51 (32) 50 (31) 34 (21)
12-month post-randomisation period 57 (38) 56 (38) 52 (36) 58 (39)
Payments from income protection schemes or private pensions
6-month pre-randomisation period 10 (6) 9 (6) 13 (8) 8 (5)
12-month post-randomisation period 12 (8) 17 (12) 22 (16) 11 (7)
APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care alone.
doi:10.1371/journal.pone.0040808.t004
Table 5. EQ-5D utilities and QALYs accrued during follow-up
period.
Time point
APT
(n=148)
CBT
(n=143)
GET
(n =143)
SMC
(n=151)
Baseline 0.48 (0.27) 0.54 (0.24) 0.52 (0.26) 0.50 (0.28)
12-week 0.53 (0.28) 0.59 (0.25) 0.54 (0.28) 0.52 (0.28)
24-week 0.54 (0.27) 0.61 (0.26) 0.60 (0.29) 0.52 (0.29)
52-week 0.54 (0.29) 0.63 (0.28) 0.59 (0.30) 0.53 (0.31)
QALYs accrued 0.53 (0.22) 0.60 (0.21) 0.57 (0.23) 0.52 (0.25)
APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET =
graded exercise therapy, SMC = specialist medical care alone.
doi:10.1371/journal.pone.0040808.t005
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regarding the value of unpaid care from family and friends and lost
employment. However, sensitivity analyses revealed that the
results were robust for alternative assumptions. Fifth, lost
employment was valued using the human capital approach. It
has been argued that this may overestimate such costs when there
is high unemployment and that costs should be confined to the
‘friction period’ during which new employees can be recruited
[25]. However, what is evident is that lost work days did not show
Figure 1. QALY-based cost-effectiveness acceptability curves (healthcare perspective).
doi:10.1371/journal.pone.0040808.g001
Table 6. Cost-effectiveness results from healthcare and societal perspectives, 0–52 weeks.
CBT v SMC APT v SMC GET v SMC
Outcome: QALYs (n = 570)
Incremental effect 0.0492 0.0149 0.0343
Incremental healthcare cost £904 £823 £810
ICER (healthcare) £18,374 per QALY £55,235 per QALY £23,615 per QALY
Incremental societal cost 2£698 £1893 2£472
ICER (societal) CBT dominant £127,047 per QALY GET dominant
Outcome: Fatigue (n = 573)
Incremental effecta 11.1 1.9 14.0
Incremental healthcare cost £898 £863 £837
ICER (healthcare) £8105 per person improved £44,715 per person improved £5987 per person improved
Incremental societal cost 2£796 £2180 2£400
ICER (societal) CBT dominant £112,953 per person improved GET dominant
Outcome: Disability (n = 577)
Incremental effecta 13.4 28.5 12.6
Incremental healthcare cost £904 £850 £842
ICER (healthcare) £6366 per person improved SMC dominant £6683 per person improved
Incremental societal cost 2£794 £1948 2£397
ICER (societal) CBT dominant SMC dominant GET dominant
aPercentage point difference between groups.
QALY = quality-adjusted life year, ICER = incremental cost-effectiveness ratio,
APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care alone.
doi:10.1371/journal.pone.0040808.t006
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much difference between the groups and alternative approaches,
while possibly reducing absolute societal costs, would not change
the cost-effectiveness results. Sixth, there is similar uncertainty
around the most appropriate way of valuing informal care [26].
Alternative approaches were used in the sensitivity analyses and
these did not make a substantial difference to the results. We
adopted the opportunity cost approach and used average wages to
reflect this value. Seventh, we analysed data only for those
participants where we had data at both baseline and follow-up.
This may have introduced some distortions to the results but there
were few differences between patients with missing data and those
on whom we had complete data. Finally, although one-year
follow-up is longer than that obtained in most previous trial of
treatments for CFS, we cannot be certain about the longer-term
cost-effectiveness of these treatments.
Conclusions
At a conventional cost-per-QALY threshold considering a one
year outcome CBT has the highest probability of being the most
cost-effective treatment option for CFS when given as a
supplement to SMC and compared to SMC alone. GET has a
lower probability of being the most cost-effective option but is
more likely to be so than APT or SMC alone. The probabilities
that CBT GET are the most cost-effective options at a societal
level are higher still, largely due to cost-savings from reducing the
care required from family members.
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